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Abstract
Background:  Bisdioxopiperazine anti-cancer agents are inhibitors of eukaryotic DNA topoisomerase II,
sequestering this protein as a non-covalent protein clamp on DNA. It has been suggested that such complexes
on DNA represents a novel form of DNA damage to cells. In this report, we characterise the cytotoxicity and
DNA damage induced by the bisdioxopiperazine ICRF-187 by a combination of genetic and molecular approaches.
In addition, the well-established topoisomerase II poison m-AMSA is used for comparison.
Results: By utilizing a panel of Saccharomyces cerevisiae single-gene deletion strains, homologous recombination
was identified as the most important DNA repair pathway determining the sensitivity towards ICRF-187.
However, sensitivity towards m-AMSA depended much more on this pathway. In contrast, disrupting the post
replication repair pathway only affected sensitivity towards m-AMSA. Homologous recombination (HR) defective
irs1SF chinese hamster ovary (CHO) cells showed increased sensitivity towards ICRF-187, while their sensitivity
towards m-AMSA was increased even more. Furthermore, complementation of the XRCC3 deficiency in irs1SF
cells fully abrogated hypersensitivity towards both drugs. DNA-PKcs deficient V3-3 CHO cells having reduced
levels of non-homologous end joining (NHEJ) showed slightly increased sensitivity to both drugs. While exposure
of human small cell lung cancer (SCLC) OC-NYH cells to m-AMSA strongly induced γH2AX, exposure to ICRF-
187 resulted in much less induction, showing that ICRF-187 generates fewer DNA double strand breaks than m-
AMSA. Accordingly, when yeast cells were exposed to equitoxic concentrations of ICRF-187 and m-AMSA, the
expression of DNA damage-inducible genes showed higher levels of induction after exposure to m-AMSA as
compared to ICRF-187. Most importantly, ICRF-187 stimulated homologous recombination in SPD8 hamster lung
fibroblast cells to lower levels than m-AMSA at all cytotoxicity levels tested, showing that the mechanism of action
of bisdioxopiperazines differs from that of classical topoisomerase II poisons in mammalian cells.
Conclusion:  Our results point to important differences in the mechanism of cytotoxicity induced by
bisdioxopiperazines and topoisomerase II poisons, and suggest that bisdioxopiperazines kill cells by a combination
of DNA break-related and DNA break-unrelated mechanisms.
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Background
Type II topoisomerases are essential nuclear enzymes
found in all living organisms [1]. Their basic role in cells
is to catalyse the transport of one DNA double helix
through a transient double strand break in another DNA
molecule [2]. This activity helps relieve tensions built up
in DNA during various DNA metabolic processes such as
DNA replication, chromosome condensation and de-con-
densation, chromosome segregation and transcription
[3].
Topoisomerase II is also a major drug target in human
cancer therapy, where a number of clinically active drugs
such as the epipodophyllotoxins VP-16 and VM-26, the
aminoacridine m-AMSA, and antracyclines such as doxo-
rubicin, daunorubicin and epirubicin are widely used.
These drugs have collectively been called topoisomerase II
poisons due to their mechanism of action on topoisomer-
ase II. Rather than inhibiting the basic catalytic activity of
the enzyme, these drugs perturb the topoisomerase II cat-
alytic cycle resulting in an increase in the level of a tran-
sient reaction intermediate, where DNA is cleaved and
covalently attached to DNA [4].
Catalytic inhibitors of topoisomerase II have a different
mode of action. These drugs exemplified by merbarone,
aclarubicin, F11782 and the bisdioxopiperazines work by
inhibiting topoisomerase II at other stages in the reaction
cycle where DNA is not cleaved as reviewed in [5,6].
Amongst these, the bisdioxopiperazines have gained
much attention due to their distinct and well-character-
ised mode of action. These compounds exemplified by
ICRF-187, ICRF-159 and ICRF-154 inhibit the DNA
strand passage reaction of topoisomerase II by sequester-
ing this protein as a salt-stable closed clamp on DNA
whose formation depends on the presence of ATP [7-9].
This closed clamp complex has retained the capability to
hydrolyse ATP, although at a reduced level [10].
Several studies indicate that the closed clamp complex on
DNA represents a novel form of DNA lesion to cells, – and
that inhibition of topoisomerase II catalytic activity (DNA
strand passage activity) is not responsible for bisdioxopi-
perazine-induced cell kill: (i) Expression of bisdioxopi-
perazine-sensitive topoisomerase II in cells also
expressing bisdioxopiperazine-resistant topoisomerase II
confers dominant sensitivity to these drugs [7,11] – a
modality reminiscent of that of topoisomerase II poisons.
(ii) Mouse embryonic stem cells [12] and chicken lym-
phoma DT40 cells [13] having one topoisomerase II α
allele knocked out with concomitant reduced levels of
topoisomerase II, are resistant to both ICRF-193 and the
topoisomerase II poison etoposide, – while the opposite
result is to be expected if ICRF-193 kill cells by depriving
them of essential topoisomerase II catalytic activity. (iii)
Killing of yeast cells by exposure to ICRF-193 occurs more
rapidly and to a higher level than killing of yeast cells
induced by the depletion of endogenous topoisomerase II
catalytic activity [7]. (iv) The ICRF-193-induced topoi-
somerase II closed clamp complexes on DNA work as a
"road block" signalling selective degradation of topoi-
somerase II β as well as p53 activation in a transcription
dependent fashion [14].
Some studies have recorded elevated levels of DNA breaks
in cells after exposure to the bisdioxopiperazine analog
ICRF-193. In one study, ICRF-193 was found to increase
the level of topoisomerase II-DNA covalent complexes in
vitro and in vivo [15]. However, in this study efficient trap-
ping of this covalent intermediate was only evident when
guanidine was used to denature topoisomerase II attracted
to DNA, while the agent normally used to trap the topoi-
somerase II-DNA cleavage complex, SDS, was not effec-
tive. In another study, the comet assay and pulsed field gel
electrophoresis were used to demonstrate elevated levels
of DNA breaks in mammalian cells after exposure to
ICRF-193 [16]. In this study, inhibiting DNA replication
with aphidicolin reduced the level of DNA breaks induced
by the topoisomerase II poison m-AMSA, but had no
effect on DNA breaks induced by ICRF-193. These results
point towards bisdioxopiperazines poisoning DNA topoi-
somerase II in cells by a mechanism different from that of
the classical topoisomerase II poisons such as etoposide
and m-AMSA. In a recent paper, it was directly
Table 1: Yeast strains used in the study
BY4741 + pMJ1 BY4741∆rad9 + pMJ1
BY4741∆rad51 + pMJ1 BY4741∆tel1 + pMJ1
BY4741∆rad52 + pMJ1 BY4741∆chk1 + pMJ1
BY4741∆rad54 + pMJ1 BY4741∆mhl1 + pMJ1
BY4741∆rad55 + pMJ1 BY4741∆pms1 + pMJ1
BY4741∆rad57 + pMJ1 BY4741∆msh2 + pMJ1
BY4741∆rad59 + pMJ1 BY4741∆msh3 + pMJ1
BY4741∆dcm1 + pMJ1 BY4741∆atr1 + pMJ1
BY4741∆sae2 + pMJ1 BY4741∆pdr5 + pMJ1
BY4741∆rad50 + pMJ1 BY4741∆yor1 + pMJ1
BY4741∆mre11 + pMJ1 BY4741∆ubc4 + pMJ1
BY4741∆xrs2 + pMJ1 BY4741∆ubc13 + pMJ1
BY4741∆rad6 + pMJ1 BY4741∆doa4 + pMJ1
BY4741∆rad18 + pMJ1 BY4741∆qri8 + pMJ1
BY4741∆rev1 + pMJ1 BY4741∆rnr3 + pMJ1
BY4741∆rev3 + pMJ1 BY4741∆sml1 + pMJ1
BY4741∆rad1 + pMJ1 BY4741 + PYX112
BY4741∆rad14 + pMJ1 BY4741∆rad6 + pYX112
BY4741∆apn1 + pMJ1 BY4741∆rad50 + pYX112
BY4741∆yku70 + pMJ1 BY4741∆rad52 + pYX112
BY4741∆yku80 + pMJ1 BY4741∆sae2 + pYX112
BY4741∆mec3 + pMJ1 BY4741∆yku70 + pYX112
BY4741∆dcc1 + pMJ1
BY4741∆rad17 + pMJ1 JN362At2-4+ pMJ1BMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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demonstrated that m-AMSA-induced dominant cytotoxic-
ity only required the DNA cleavage activity of topoisomer-
ase II, while dominant cytotoxicity towards ICRF-193
depended strictly on the DNA strand passage reaction of
the enzyme[17].
Based on these observations, the present study aims to fur-
ther elucidate the mechanism of cytotoxicity induced by
the bisdioxopiperazines. We here characterise the effect of
the clinically approved analog ICRF-187 (dexrazoxane)
by using a number of different cell-based pharmacological
assays, taking advantage of genetically modified yeast and
mammalian cells.
Results
ICRF-187 sensitivity of yeast cells depends on their 
homologous recombination status, albeit to a lesser extent 
than for m-AMSA sensitivity
To pinpoint the mechanism of cytotoxicity of ICRF-187
versus m-AMSA, we employed a panel of human topoi-
somerase II α-transformed haploid single-gene knockout
yeast strains, defective in various aspects of DNA repair,
checkpoint control, membrane transport and protein deg-
radation. All yeast strains are depicted in table 1. We used
doses of these two drugs equitoxic to wild-type cells hav-
ing no mutations. Clonogenic survival of all yeast strains
is depicted in additional file 1, and the degree of drug
resistance / hypersensitivity is also listed in table 2.
The products of the three genes RAD50, MRE11 and XRS2
together form the Rad50/Mre11/Xrs2 hetero-trimer pro-
tein complex that has catalytic and structural functions in
many kinds of DNA metabolic processes including HR as
Table 2: Hypersensitivity (or resistance) scoring of pMJ1-
transformed BY4741 deletion strains towards ICRF-187 and m-
AMSA as determined in clonogenic assay using 22.5 hours drug 
exposure.
Drug ICRF-187 m-AMSA
Gene deleted
WT 00
Nucleotide Excision Repair 
(NER)
Single Strand Annealing (SSA) 
Recombination
Anti-Recombination
∆rad1 R0
∆rad14 00
Mismatch Repair (MMR)
Anti-Recombination
∆msh2 R0
∆msh3 00
∆mhl1 R0
∆pms1 R0
Base Excision Repair (BER)
∆apn1 00
Post Replication Repair (PRR)
∆rev1 00
∆rev3 00
∆rad18 0+
∆rad6 0+ +
Homologous Recombination 
(HR)
Non-Homologous End Joining 
(NHEJ)
∆rad50 ++ +
∆mre11 ++ +
∆xrs2 ++ +
Homologous Recombination 
(HR)
∆rad52 ++ +
∆rad51 ++
∆rad54 ++ +
∆rad57 ++ +
∆rad55 ++ +
∆rad59 00
∆dmc1 00
∆sae2 ++
Non-Homologous End Joining 
(NHEJ)
∆yku70 +0
∆yku80 00
DNA Damage Checkpoints
∆tel1 00
∆rad9 00
∆mec3 00
∆ddc1 00
∆rad17 00
∆chk1 00
ABC Transporters (Yeast 
MDR1 homologous)
∆atr1 00
∆pdr5 +0
∆yor1 00
Ubiquitin conjugation / 
hydrolysis
∆ubc4 00
∆ubc13 00
∆doa4 0R
∆qri8 00
Ribonucleotide-reductase 
regulation
∆rnr3 00
∆sml1 00
R : Cells are more than a 1/2 log resistant at any drug concentration.
0 : Cells are no more than a 1/2 log resistant and no more than a 1/2 
log hypersensitive at any drug concentration.
+ : Cells are at least a 1/2 log but no more than 2 log hypersensitive at 
any concentration.
++ : Cells are more than 2 log hypersensitive at any concentration.
Hypersensitivity (resistance) was graduated as follows
Table 2: Hypersensitivity (or resistance) scoring of pMJ1-
transformed BY4741 deletion strains towards ICRF-187 and m-
AMSA as determined in clonogenic assay using 22.5 hours drug 
exposure. (Continued)BMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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reviewed in [18]. We observed that ∆rad50, ∆mre11, and
∆xrs2 single knockout strains were extremely hypersensi-
tive towards m-AMSA, while they displayed considerably
less hypersensitivity towards ICRF-187 (additional file 1
and table 2).
We also tested the effect of deleting a number of genes
exclusively involved in HR namely RAD51,  RAD52,
RAD54, RAD55, RAD57, RAD59, DMC1 and SAE2 [18].
Deleting  RAD51,  RAD52,  RAD54,  RAD55,  RAD57  and
SAE2 had a profound effect on the sensitivity of the yeast
cells towards m-AMSA while having a smaller, but signifi-
cant, effect on the sensitivity of these cells towards ICRF-
187 (additional file 1 and table 2), again pointing to the
HR pathway as being most important for the repair of
DNA damage caused by cleavage complex stabilising
drugs. We found that deleting RAD59 had no effect on
drug sensitivity, confirming reported data that RAD59
only becomes functionally important in the absence of
functional Rad51 protein [19]. We also observed no effect
of deleting DMC1 (additional file 1 and table 2). This may
be explained by the fact that Dmc1p is primarily involved
in meiotic recombination [20].
NHEJ represents another DNA repair-pathway. In yeast,
this repair pathway is generally less important than HR for
the repair of DNA breaks [21]. In accordance with this we
observed no effect of deleting the NHEJ genes YKU70 and
YKU80 on the sensitivity towards m-AMSA. We did how-
ever, observe some hypersensitivity of ∆yku70  cells
towards ICRF-187, while ∆yku80  cells were not
hypersensitive (additional file 1 and table 2). This is a sur-
prising result, because Yku70p and Yku80p have been
demonstrated to play equally important roles for NHEJ
activity in yeast [21]. These results suggest that the effect
of deleting YKU70  is unrelated to its DNA repair
functions.
The DNA binding Rad18p forms a hetero-dimer with
Rad6p that is involved in post replication repair (PRR)
[22]. We found that although ∆rad18 cells were clearly
hypersensitive towards m-AMSA, ∆rad6 cells were mark-
edly more sensitive. ∆rad6 cells were actually among the
most sensitive towards m-AMSA (figure 1, additional file
1 and table 2). Interestingly, the sensitivity of ∆rad6 and
∆rad18 cells towards ICRF-187 is indistinguishable from
that of wild-type cells (figure 1). The vast difference in the
sensitivity of ∆rad6 cells towards ICRF-187 and m-AMSA
confirms the notion that the DNA lesions induced by
these drugs are different in nature. The finding that ∆rad6
cells are much more sensitive towards m-AMSA than
∆rad18 cells is surprising, and may indicate that Rad6p
functions unrelated to DNA repair affect cellular sensitiv-
ity towards m-AMSA. Rad6p has ubiquitin conjugating
activity [22], and therefore such Rad18p-unrelated func-
tions could involve protein degradation via the 26S pro-
teasome pathway. To test this hypothesis, we analysed the
drug sensitivity of four yeast strains with impaired protein
degradation; ∆ubc4, ∆ubc13, ∆doa4 and ∆qri8. These dele-
tion strains were not hypersensitive towards m-AMSA (or
ICRF-187) (additional file 1 and table 2), suggesting that
∆rad6  cells are hypersensitive towards m-AMSA due to
impaired PRR activity. The involvement of both HR repair
and PRR in determining the sensitivity of yeast cells
towards the topoisomerase II cleavage complex stabilising
drugs mitoxantrone and idarubicin has previously been
reported [23]. The observed lack of hypersensitivity of the
∆rev1 and ∆rev3 strains (additional file 1 and table 2) sug-
gests that trans-lesion DNA synthesis plays no role in
determining the sensitivity towards ICRF-187 or m-AMSA.
We also analysed the effect of deleting genes belonging to
the nucleotide excision repair (NER) pathway – RAD1 and
RAD14, the base excision repair (BER) pathway – APN1,
and the mismatch repair (MMR) pathway – MLH1, PMS1,
MSH2 and MSH3. None of these deletions caused cells to
become more sensitive towards ICRF-187 and m-AMSA,
indicating that these pathways are not involved in repair-
ing DNA damage induced by these drugs. Interestingly,
deleting genes involved in the MMR and NER pathways
caused cells to become somewhat resistant to ICRF-187,
and to a lesser extent towards m-AMSA (additional file 1
and table 2). The products of these genes have been impli-
cated to have anti-recombination activities [24]. Increased
levels of recombination in these cells could therefore be
responsible for the observed low-level resistance towards
ICRF-187.
Deletion of DNA damage checkpoint genes has little effect 
on both ICRF-187 and m-AMSA sensitivity of yeast cells
While deleting genes involved in DNA repair caused cells
to be hypersensitive towards both drugs tested, we
observed little effect of deleting the DNA damage check-
point genes MEC3,  DDC1,  RAD17,  TEL1,  RAD9  and
CHK1 (additional file 1 and table 2). Our finding that
checkpoint control regulation plays no important role for
bisdioxopiperazine sensitivity supports earlier data show-
ing that arresting yeast cells in G1 phase did not protect
against ICRF-193 cytotoxicity [7]. The lack of importance
of checkpoint function in determining sensitivity towards
m-AMSA is also in accordance with published observa-
tions [23], where sensitivity towards the cleavage complex
stabilising topoisomerase II poisons mitoxantrone, idaru-
bicin, daunorubicin and doxorubicin were only margin-
ally affected by inactivating the RAD9, RAD17, MEC1, and
RAD53 genes, while the sensitivity of yeast cells towards
the topoisomerase I poison camptothecin showed a
strong dependency on these pathways.BMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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ICRF-187 is a possible substrate for the Pdr5 ABC 
transporter in yeast
In mammalian cells resistance towards various structur-
ally-unrelated anti-neoplastic agents is often associated
with over-expression of ABC-type drug efflux transporters
such as p-glycoprotein and multi-drug resistance protein
(MRP) as reviewed in [25]. Among the three yeast ABC
transporters assessed in our study, Pdr5 is by far the best
characterised [26]. While deleting YOR1 and ATR1 had no
effect on drug sensitivity, ∆pdr5 cells were clearly hyper-
sensitive towards ICRF-187 but not towards m-AMSA
(additional file 1 and table 2), suggesting that ICRF-187 is
a substrate for the Pdr5 pump in yeast. It has to be empha-
sized, that over-expression of drug efflux pumps has not
been associated with resistance towards bisdioxopipera-
zines in mammalian cells.
Transcriptional profiling of yeast cells after exposure to 
equitoxic concentrations of ICRF-187 and m-AMSA
In order to assess the effect on global gene expression of
the interaction between human topoisomerase II α and
the two drugs in yeast cells, transcriptional profiling was
performed using Affymetrix gene chip technology. We
exposed pMJ1-transformed JN362At2–4 yeast cells express-
ing human topoisomerase II α as their sole active topoi-
somerase II to equitoxic doses of ICRF-187 and m-AMSA
for two hours at 34°C. This treatment resulted in a 50 %
reduction in clonogenic survival after exposure to both
drugs (additional file 2). Genes whose average expression
Clonogenic sensitivity of PRR defective ∆rad6 and ∆rad18 yeast cells towards equitoxic doses of ICRF-187 and m-AMSA Figure 1
Clonogenic sensitivity of PRR defective ∆rad6 and ∆rad18 yeast cells towards equitoxic doses of ICRF-187 and m-AMSA. A 
∆rad52 strain is included for comparison. Error-bars represent SEM of at least 3 experiments.
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in two independent experiments was up- or down-regu-
lated more than 1.5 fold by exposure to the drugs were fil-
tered out. 138 transcripts were induced by exposure to
ICRF-187 while the number was 90 for m-AMSA. 26 tran-
scripts were repressed by exposure to ICRF-187 while the
number was 16 for m-AMSA. Additional file 3 lists tran-
scripts induced or repressed by ICRF-187 while additional
file 4 lists transcripts induced or repressed by m-AMSA.
The expression profile of selected genes is listed in Table 3
and discussed below.
Genes induced by both drugs
Both compounds induced the expression of a number of
genes known to be up-regulated by DNA damage. The
expression of four well-established DNA-damage induci-
ble genes; RNR2, RNR3 [27,28] and RAD51, RAD54 [29]
was thus induced by both drugs. Both compounds also
stimulated the expression of HUG1 recently shown to be
up-regulated by DNA damage and replication arrest [30]
(See Table 3, additional files 3 and 4). Furthermore, both
drugs stimulated expression of the stress-inducible XBP1
gene whose protein product is a transcription factor. XBP1
expression is reportedly induced in response to heat
shock, high osmolarity, oxidative stress, glucose starva-
tion and DNA damage, and induces a slow-growth pheno-
type with lengthening of the G1 cell cycle phase [31]. The
PCL9 gene product has cyclin-dependent protein kinase
regulator activity suggesting a role for Pcl9p in cell cycle
regulation [32]. Repression of PCL9 by exposure to both
drugs (table 3, additional files 3 and 4) may thus be indic-
ative of drug-induced cell cycle arrest in accordance with
the XBP1 expression data. Finally, both drugs induced the
expression of general stress-induced HSP  genes as
expected (table 3, additional files 3 and 4). Although
expression of the RNR3 and HUG1 genes was up-regu-
lated by both drugs, pMJ1-transformed cells having RNR3
or SML1 deleted (the latter is a functional non-inducible
homolog of HUG1) have wild-type sensitivity towards
both drugs (table 2, additional file 1), showing that
although these genes are induced by both drugs, they are
probably not involved in determining their cytotoxicity.
Genes specifically induced by ICRF-187
We found that ICRF-187 specifically induced the expres-
sion of two genes encoding the ABC efflux transporters
Pdr12 and Pdr15, while m-AMSA had no effect on the
expression of these genes (table 3, additional files 3 and
4). Transcription of the stress-inducible WSC4 gene was
likewise enhanced by exposure to ICRF-187 (table 3, addi-
tional files 3 and 4). Knocking out WSC4 in yeast cells has
been found to enhance their sensitivity towards various
stresses including heat, ethanol and DNA damage [33].
Recently, the SWI/SNF complex was directly shown to
repress transcription in S. cerevisiae cells [34]. We found
that SWI1 was specifically induced by ICRF-187 (table 3,
additional files 3 and 4). Finally, we found that ICRF-187
specifically repressed the expression of the stationary
phase-induced SNZ1 gene [35] (table 3, additional files 3
and 4).
Exposure of yeast cells to ICRF-187 causes less 
transcriptional induction of DNA damage-inducible genes 
Table 3: Selected genes induced or repressed by exposure of pMJ1-transformed yeast cells to equitoxic concentrations of ICRF-187 
and m-AMSA for 2 hours
Transcriptional activation
Gene function Gene Name Effect of ICRF-187 Effect of m-AMSA
DNA damage RNR3 3.2 4.0
HUG1 3.1 5.0
RAD51 1.9 2.0
RAD54 1.7 1.6
RNR2 1.5 1.8
Membrane transport PDR12 2.4 1.0
PDR15 2.0 1.0
Stress response HSP12 2.8 1.6
HSP26 1.7 1.8
WSC4 1.6 1.3
XBP1 1.6 1.5
HSP42 1.5 1.5
Others SWI1 1.6 1.1
Transcriptional repression
Others SNZ1 0.6 1.1
PCL9 0.7 0.6BMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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than exposure to m-AMSA at equitoxic drug 
concentrations
To verify the array data we performed real-time PCR to
assess the expression of the RNR3, HUG1, RAD51 and
RAD54 genes after exposure to the two drugs using the
actin gene ACT1 as internal control (figure 2). Real-time
PCR confirmed induction of these established DNA dam-
age-inducible genes by both drugs assessed. Furthermore,
exposure of the cells to m-AMSA resulted in a higher level
of induction than did exposure to ICRF-187 for the four
genes tested, especially for HUG1. These data suggest that
when yeast cells are exposed to equitoxic concentrations
of the two drugs, m-AMSA generates more extensive DNA
damage than ICRF-187.
ICRF-187 sensitivity of mammalian hamster cells depends 
on their homologous recombination status, albeit to a 
lesser extent than seen for m-AMSA sensitivity
The yeast clonogenic assays presented above point to an
important role of HR in the repair of m-AMSA-induced
DNA damage, while the importance of this pathway in the
repair of ICRF-187-induced DNA damage is less so.
Because HR is the major repair pathway in yeast [21],
while both NHEJ and HR are important for the repair of
DNA breaks in mammalian cells [36], we next turned to
assess the importance of these pathways in mammalian
cells having reduced levels of HR and NHEJ. In this
analysis we used a panel of four hamster cell lines; AA8
cells (wild-type), irs1SF cells [37] (recombination defec-
tive caused by non-functional XRCC3), CXR3 cells [37]
(recombination proficient due to ectopic expression of
Analysis of gene expression by real time PCR Figure 2
Analysis of gene expression by real time PCR. Real-time PCR 
was used to determine the expression of the DNA-damage 
inducible genes RNR3, HUG1, RAD51, and RAD54 by using the 
2-∆∆Ct method. Gene expression was normalized to that of 
the actin gene ACT1. It can be seen that exposure of yeast 
cells to m-AMSA results in higher levels of induction of tran-
scription of these four genes than exposure to ICRF-187 
when the two drugs are applied at equitoxic concentrations. 
Error-bars represent SEM of two independent experiments 
each performed in duplicate.
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Assessing the clonogenic sensitivity of HR and NHEJ deficient  and proficient hamster cells towards ICRF-187 and m-AMSA Figure 3
Assessing the clonogenic sensitivity of HR and NHEJ deficient 
and proficient hamster cells towards ICRF-187 and m-AMSA. 
To determine the sensitivity of the four cell lines AA8 (wild-
type), irs1SF (recombination defective caused by non-func-
tional XRCC3), CXR3 (recombination proficient due to 
ectopic expression of human XRCC3), and V3-3 (defective in 
NHEJ due to non-functional DNA-PKcs) towards ICRF-187 
and m-AMSA, a clonogenic assay with continuous drug expo-
sure was used. Error-bars represent SEM of two independ-
ent experiments.
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human XRCC3), and V3-3 cells [38] (reduced level of
NHEJ due to non-functional DNA-PKcs).
We observed a strong dependence on HR for the sensitiv-
ity towards m-AMSA (figure 3A). Thus, only 1 % relative
survival was seen for the irs1SF cells (recombination
defective) at 6 nM of this drug, while wild-type AA8 cells
were only slightly sensitive to15 nM m-AMSA. Further-
more, ectopic expression of human XRCC3 fully reversed
the m-AMSA hypersensitivity as CXR3 cells were no more
hypersensitive than AA8 wild-type cells, confirming the
notion that HR plays a role in the repair of topoisomerase
II-induced DNA breaks in mammalian cells. We also
observed that irs1SF cells were hypersensitive towards
ICRF-187 (figure 3B), but the degree of hypersensitivity
was much less than observed for m-AMSA, as also seen for
recombination deficient yeast cells. Again, ectopic expres-
sion of the human XRCC3  homolog reversed the
hypersensitivity as CXR3 cells displayed near wild-type
sensitivity towards ICRF-187.
DNA-PKcs deficient hamster cells show slightly increased 
sensitivity towards both m-AMSA and ICRF-187
To assess the effect of NHEJ on drug sensitivity we also
employed the V3-3 cell line (DNA-PKcs deficient, with
concomitant reduced level of NHEJ). The results of these
experiments are depicted in figure 3A and 3B. The V3-3
cells were slightly hypersensitive towards both drugs
suggesting a role for NHEJ in the repair of DNA lesions
induced by both drugs.
AA8, irs1SF, CXR3 and V3-3 cells have similar levels of 
topoisomerase II catalytic activity
The sensitivity of cells towards topoisomerase II directed
drugs depends both on their levels of topoisomerase II
catalytic activity, and on their capability to repair topoi-
somerase II-induced DNA damage. We therefore deter-
mined the level of topoisomerase II catalytic (DNA strand
passage) activity in crude protein extracts isolated from
the four cell lines used in clonogenic assays, by applying a
radioactive decatenation assay. No significant difference
in the level of topoisomerase II DNA strand passage activ-
ity was recorded between the four cell lines (additional
file 5). This result rules out the possibility that varying
levels of topoisomerase II catalytic activity in these cells is
responsible for their differential drug sensitivity.
ICRF-187 induces lower levels of homologous 
recombination in hamster cells than m-AMSA at equitoxic 
concentrations
The hypersensitivity of the recombination defective irs1SF
cells towards both drugs suggests that HR is involved in
repairing DNA lesions induced by both drugs. To address
this directly we applied a mammalian recombination
assay to measure stimulation of HR by ICRF-187 and m-
AMSA by using SPD8 hamster cells [39]. This assay meas-
ures the repair of a defective chromosomal hprt gene by
the activity of HR. From figure 4A it is evident that both
drugs stimulated the level of HR in a dose dependent
manner. When recombination frequency is expressed as a
function of surviving cells (figure 4C) it becomes evident
that the recombination frequency increases with
increasing cell mortality for both drugs tested. From figure
4C it is also evident that at equitoxic concentrations of the
two drugs, m-AMSA stimulated HR to much higher levels
than did ICRF-187. Thus, at 50 % survival, no induction
of HR was seen with ICRF-187 (in three independent
experiments), while m-AMSA caused an approximately
10-fold induction at equitoxic doses.
ICRF-187 induces only low levels of H2AX phosphorylation 
in human SCLC cells as compared to m-AMSA
Induction of γH2AX is a well-established marker for
topoisomerase-induced DNA double strand breaks in
mammalian cells [40-42]. We therefore assessed the effect
of exposing human SCLC OC-NYH cells to 10 µM m-
AMSA and 1 mM of ICRF-187 at increasing time points
(figure 5A and 5B). Exposure to 10 µM m-AMSA quickly
resulted in γH2AX induction. Thus, induction was evident
after 30 min, and after 24 hours more than 10-fold induc-
tion was observed. In contrast, when cells were exposed to
1 mM ICRF-187, much less γH2AX induction was
observed, and after 24 hours the level of induction was
less that three-fold.
Discussion
We initiated the study by assessing the clonogenic sensi-
tivity of yeast single-gene deletion mutants ectopically
expressing human topoisomerase II α towards m-AMSA
and ICRF-187. The results presented in table 2 and addi-
tional file 1 indicates that HR plays a role in the repair of
ICRF-187-induced DNA damage. Previous studies
addressing the bisdioxopiperazine sensitivity of yeast cells
have generated different results. In one study rad52-cells
had the same sensitivity towards ICRF-187 and ICRF-193
as did RAD52+ cells [7], while in other studies, HR defi-
cient cells were found to be hypersensitive towards bisdi-
oxopiperazines, although to a much lesser extent than
towards topoisomerase II cleavage complex stabilising
drugs [43,44]. Our present study involving numerous
other genes involved in various aspects of HR clearly
establishes this pathway as being a functional determi-
nant for bisdioxopiperazine sensitivity in yeast cells. In a
recent work by Simon and colleagues, where a panel of
yeast deletion strains was also applied to pinpoint the
mechanism of action of various anticancer drugs, a given
drug was classified as selective if one single pathway was
mainly involved in determining cellular sensitivity [23].
The selective involvement of the HR pathway in determin-
ing the sensitivity towards ICRF-187 classifies this drug asBMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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highly selective according to this definition. However, it is
important to note that although HR clearly does play a
role in protecting yeast cells from ICRF-187 cytotoxicity,
the importance of this pathway on cell survival in the
presence of m-AMSA is much greater (additional file 1,
table 2) – in accordance with this drug being a topoi-
somerase II poison killing cells solely by the generation of
topoisomerase II-mediated DNA breaks.
We find that the relative sensitivity of AA8, irs1SF, and
CXR3 cells towards m-AMSA (figure 3) closely resembles
their sensitivity towards etoposide [45], showing that the
hypersensitivity of XRCC3 deficient irs1SF cells is general
to topoisomerase II poisons, suggesting a role for HR in
the repair of topoisomerase II-induced DNA breaks in
these cells. The involvement of HR in the repair of DNA
lesions induced by topoisomerase II poisons in higher
eukaryotes is also supported by a recent work suggesting
that RAD51 plays an important role in the repair of etopo-
side-induced DNA damage in human small cell lung can-
cer cells [46], and by work by Adachi and colleagues who
recently found that knocking out RAD54 in chicken DT40
cells enhances their sensitivity towards the topoisomerase
II poison etoposide [13].
Assessing the effect of equitoxic concentrations of ICRF-187 and m-AMSA on the level of HR in SPD8 hamster cells Figure 4
Assessing the effect of equitoxic concentrations of ICRF-187 and m-AMSA on the level of HR in SPD8 hamster cells. The SPD8 
cell line has a defective hprt gene that can be repaired by HR. Panel A depicts the induction of HR induced by increasing con-
centrations of the two drugs. Panel B depicts the relative survival of cells exposed to similar concentrations of the two drugs. 
The data represented in Panel A and B was used to generate Panel C, where recombination frequency is plotted against the 
surviving fraction of cells. This data presentation allows a direct comparison of recombination levels at equitoxic concentra-
tions of the two drugs. Representative data from one of three independent experiments is shown.
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We find that XRCC3 defective irs1SF cells are more sensi-
tive towards ICRF-187 than the parental AA8 cells,
although the XRCC3 defect has a much more pronounced
effect on m-AMSA sensitivity (figure 3A versus figure 3B)
– as seen with the yeast deletion mutant panel. Adachi
and colleagues have found that knocking out RAD54 in
DT40 chicken cells does not increase sensitivity towards
ICRF-193 [13]. The reason for this discrepancy in not
clear. The difference observed between the DT40 and
irs1SFcells may relate to the fact that different DNA repair
genes are deleted in the two cell lines possibly resulting in
different processing of bisdioxopiperazine-induced DNA
damage. In any case, this discrepancy does not challenge
the overall finding that HR plays a more important role in
protecting cells of various origin from cytotoxicity
induced by topoisomerase II poisons as compared to cyto-
toxicity induced by bisdioxopiperazines.
To study the importance of NHEJ in determining the sen-
sitivity towards m-AMSA and ICRF-187 we employed a
DNA-PKcs defective hamster cell line, V3-3, which has
reduced levels of NHEJ activity. We find that V3-3 cells are
Assessing the effect of m-AMSA and ICRF-187 on γH2AX induction in human SCLC OC-NYH cells Figure 5
Assessing the effect of m-AMSA and ICRF-187 on γH2AX induction in human SCLC OC-NYH cells. To assess the level of 
DNA breaks in human cells after exposure to 10 µM m-AMSA and 1 mM ICRF-187 for increasing time points, total histones 
were isolated after incubation with the drugs. 10 µg of purified histones was then used in western blotting experiments. Panel 
A depicts a typical Western blot showing increased γH2AX induction with increasing drug incubation times. Panel B depicts 
fold γH2AX induction plotted against drug incubation time to analyse the kinetics of induction of DNA double strand breaks by 
the two drugs. Insert shows γH2AX induction from 0 to 2 hours for better resolution. Error-bars represent SEM of three 
independent experiments for ICRF-187 treatment and SEM of two independent experiments for m-AMSA treatment.
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hypersensitive towards m-AMSA (figure 3A). This result is
in accordance with a recent publication by Willmore and
colleagues who found that a specific small-molecule
inhibitor of DNA-PKcs  NU7026 could potentate the
sensitivity of human leukemic K562 cells towards various
topoisomerase II poisons [47]. Our result is also in
accordance with a recent report by Adachi and colleagues
showing that DNA-PKcs knockout chicken DT40 cells are
hypersensitive towards etoposide [48]. These result points
towards an important role of DNA-PKcs in determining
the sensitivity of higher vertebrate cells towards topoi-
somerase II poisons. Different studies have demonstrated
a more pronounced effect of inactivating Ku as compared
to DNA-PKcs on cellular sensitivity towards topoisomerase
II poisons [48-50]. Consequently, the importance of
NHEJ in determining the sensitivity towards topoisomer-
ase II poisons in mammalian cells is likely to be underes-
timated from our V3-3 cell data. This notion is confirmed
by early publications demonstrating that Ku deficient
hamster cells are highly sensitive towards m-AMSA and
etoposide [51,52].
Our finding that V3-3 cells are more sensitive towards
ICRF-187 than AA8 cells (figure 3B) is also in accordance
with observations by Adachi and colleagues who find that
DNA-PKcs deficient chicken DT40 cells are hypersensitive
towards another bisdioxopiperazine analog, ICRF-193.
These authors found the effect of inactivating DNA-PKcs to
be much more pronounced than seen in our present
study. While the reason for this difference is not clear, it
has to be mentioned that studies addressing the effect of
DNA-PKcs on the sensitivity towards topoisomerase II tar-
geting drugs and ionising radiation have produced vary-
ing results. Thus, in a study by Jin and colleagues, DNA-
PKcs  defective murine cells were much less sensitive
towards etoposide than Ku70 and Ku80 deficient cells
[50], while in a study by Gao and colleagues the impor-
tance of DNA-PKcs on the sensitivity towards ionising
radiation was found to depend on cell type and/or cell
cycle distribution [49]. Such variation could well explain
the different importance of DNA-PKcs observed in our
study and in the work by Adachi and colleagues.
In order to study directly the effect of exposing mamma-
lian cells to ICRF-187 and m-AMSA on the levels of HR,
we employed a mammalian recombination assay previ-
ously described [39]. In this assay, m-AMSA enhanced the
level of recombination in SPD8 cells to higher levels than
ICRF-187 at all cytotoxicity levels tested (figure 4C), dem-
onstrating directly pronounced differences in the mecha-
nism(s) by which topoisomerase II poisons and
bisdioxopiperazines kill cells. This notion is further con-
firmed by our γH2AX induction experiments, where ICRF-
187 causes much lower levels of induction (figure 5),
demonstrating that ICRF-187 induces less DNA breaks in
cells than m-AMSA. Our observation that ICRF-187
induces both HR and γH2AX induction in mammalian
cells, is in agreement with a recent paper demonstrating
by the use of comet assay and pulsed field gel electrofore-
sis that ICRF-193 induces DNA breaks in mammalian
cells [16]. This result is also in agreement with our real-
time PCR results where ICRF-187 tended to induce the
expression of established DNA damage-inducible genes.
The finding that ICRF-187 induces lower levels of HR than
m-AMSA in SPD8 cells at equitoxic doses may be
explained in at least two ways. Bisdioxopiperazine-
induced DNA breaks could be more toxic to cells than
breaks induced by topoisomerase II poisons, or the DNA
breaks could be only partly responsible for killing the
cells. Three lines of evidence support the latter possibility.
(i) Functional ATR, but not ATM, is required for a cell
cycle checkpoint arrest induced by ICRF-193 [53], suggest-
ing that DNA breaks are not involved in triggering the
checkpoint signal. (ii) Exposure of mammalian cells to
the topoisomerase II poison etoposide induces degrada-
tion of the large subunit of RNA polymerase II indicative
of DNA breaks, while this is not the case for ICRF-193
[14]. (iii) Our finding that cell survival in the presence of
ICRF-187 depends less on HR than cell survival in the
presence of m-AMSA suggests that ICRF-187-induced
DNA breaks contribute less to overall cytotoxicity than m-
AMSA-induced DNA breaks. If ICRF-187-induced DNA
breaks were more toxic to cells than m-AMSA-induced
DNA breaks, cell survival in the presence of ICRF-187
would be expected to depend at least as much on HR as
cell survival in the presence of m-AMSA. This is not the
case.
What mechanisms are then responsible for producing the
DNA breaks induced by bisdioxopiperazines in cells? In a
recent work by Oestergaard and colleagues).)[17], it is
suggested that the toxic intermediate causing bisdioxopi-
perazine cytotoxicity is topoisomerase II stably bound to
two DNA segments – a conformation they suggested
would only be attainable if the DNA strand passage reac-
tion of topoisomerase II is functioning. HR could then be
required for the repair of DNA breaks generated by the
collision of DNA tracking complexes with such four-way
DNA junctions / topoisomerase II closed clamp com-
plexes on DNA. It has recently been demonstrated by the
use of pulsed field gel electrophoresis, that inhibiting
DNA replication by aphidicolin does not reduce the level
of DNA breaks generated by exposure of mammalian cells
to ICRF193, while the level of m-AMSA-induced DNA
breaks was reduced by aphidicolin treatment [16]. This
result suggests that collision of the DNA replication com-
plex with bisdioxopiperazine-induced topoisomerase II
closed clamp complex on DNA is not involved in generat-
ing the DNA breaks.BMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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In a recent study by Lundin and colleagues, it was demon-
strated that inhibiting DNA replication by exposing cells
to hydroxyurea resulted in the generation of DNA breaks
[54]. Furthermore, in this work as well as in a subsequent
work [45], HR was shown to be functionally involved in
repairing such DNA breaks. The first of these two studies
used the same four hamster cell lines that are also used in
our present study. Remarkably, the relative sensitivity of
these cell lines towards hydroxyurea exactly resembles
their sensitivity towards ICRF-187 seen in our present
work. This may suggest that replication arrest is involved
in generating DNA breaks induced by bisdioxopipera-
zines in cells. Here, replication forks stalled at the bisdiox-
opiperazine-induced closed clamp complexes could be
the source of DNA breaks in newly replicated DNA [54].
This would also explain the lack of effect of aphidicolin
on the level of ICRF-193-induced DNA breaks observed
by Hajji and colleagues [16]. If the DNA breaks result
from arrested replications forks, and not from the colli-
sion of the DNA replication complex with the closed
clamp complex on DNA, no effect of aphidicolin would
be expected. This mechanism would also explain why
yeast cells arrested in intra-S phase are not protected from
ICRF-193 cytotoxicity [7]. We therefore suggest that this
mechanism is responsible for generating DNA breaks
induced by bisdioxopiperazines in cells.
Together our HR, γH2AX, and cytotoxicity data suggest
that bisdioxopiperazines kill cells by a combination of
DNA break-related and DNA break-unrelated mecha-
nisms. This raises the question as to which mechanism(s)
is / are involved in mediating the DNA break-unrelated
part of bisdioxopiperazine cytotoxicity. Exposure of mam-
malian cells to ICRF-193 represses global transcription
and mediates selective degradation of topoisomerase II β
via a transcription dependent mechanism [14]. Inhibition
of the RNA polymerase II – transcription complex by bis-
dioxopiperazine-induced topoisomerase II complexes on
DNA could therefore be involved in mediating the DNA
break-unrelated component of bisdioxopiperazine
cytotoxicity.
Treatment of mammalian cells with high doses of ICRF-
187 for one hour is capable of antagonising DNA breaks
and the cytotoxicity of topoisomerase II poisons [55,56],
and this antagonism can be extended to animal models,
where ICRF-187 can antagonise etoposide toxicity [57,58]
and bone marrow depression (unpublished results). How
are bisdioxopiperazines capable of antagonising the
effects of topoisomerase II while at the same time produc-
ing DNA breaks? Two independent studies assessing the
dose- and schedule-dependency of combinations of bisdi-
oxopiperazines and topoisomerase II poisons on cytotox-
icity in mammalian cells may provide important clues.
One study investigated the effect of combinations of
ICRF-193 and etoposide [59]. Here, continuous adminis-
tration of low doses of both drugs resulted in synergistic
cell kill, while treatment with high concentrations of
ICRF-193 for one hour efficiently antagonised etoposide-
mediated cytotoxicity. A similar effect of schedule and
concentration on cytotoxicity has also been observed for
combinations of ICRF-187 and daunorubicin [60], but
here long time exposure of the cells to both drugs resulted
in an additive effect on cell kill. We have previously
shown that exposure of mammalian cells to high concen-
trations of ICRF-187 (500 – 1000 µM) alone for 60 min is
non-toxic, and that this treatment efficiently antagonises
etoposide-induced DNA breaks and cytotoxicity [61,62].
In these studies, exposure of cells to 200 µM ICRF-187 was
found to trap most cellular topoisomerase II α and β as
non-extractable complexes on DNA. The inability of
topoisomerase II poisons to act on bisdioxopiperazine-
stabilised closed clamp complexes on DNA could there-
fore explain the antagonistic effect of high concentrations
of bisdioxopiperazines generally observed in one-hour
drug exposure experiments [59-62]. When a low concen-
tration of bisdioxopiperazine is administered, it is most
likely that only a small fraction of the topoisomerase II
molecules in the cell is trapped as closed clamp complexes
on DNA, leaving some or most topoisomerase II mole-
cules available for the action of topoisomerase II poisons.
Therefore, after long-time exposure of cells to low concen-
trations of bisdioxopiperazine and a topoisomerase II poi-
son, covalent and non-covalent complexes of
topoisomerase II on DNA could both contribute to cyto-
toxicity by generating DNA breaks via different mecha-
nisms, thus explaining the additive or synergistic effect on
cell kill observed under these circumstances.
To summarise, our data are consistent with a model where
bisdioxopiperazine-induced cytotoxicity results from a
combination of DNA break-related and -unrelated mech-
anisms, where the DNA-break unrelated mechanism is
clearly not mediated by the inhibition of catalytic topoi-
somerase II activity in the cells.
Conclusion
Since the discovery by Andoh and colleagues in 1991, that
the bisdioxopiperazines target eukaryotic topoisomerase
II [63,64], their mode of cytotoxicity has been the cause of
debate. While early publications tended to classify these
compounds as "pure" catalytic inhibitors of
topoisomerase II, expected to kill cells by depriving them
of essential topoisomerase II catalytic activity, numerous
recent reports present data that are not consistent with
this view [7,11-14,16,17]. In the present report we have
characterised bisdioxopiperazine (ICRF-187) induced
cytotoxicity in yeast and mammalian cells by using a com-
bination of genetic and molecular approaches. Our results
are consistent with a model where bisdioxopiperazinesBMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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cause cytotoxicity by stabilising a topoisomerase II reac-
tion intermediate / complex on DNA inducing DNA
breaks in cells which are repaired by HR and NHEJ. We
propose that cells exposed to bisdioxopiperazines die by a
combination of DNA break-related and-DNA break-unre-
lated mechanisms. Our study clearly establishes that bis-
dioxopiperazines do not kill cells solely by depriving
them of topoisomerase II catalytic activity.
Methods
Drugs
ICRF-187 (Cardioxane, Chiron group) was dissolved in
sterile water at 20 mg/ml and kept at – 80°C. To avoid
hydrolysis of the drug, fresh aliquots were used for each
experiment. m-AMSA (Pfizer) was diluted in DMSO and
stored at – 80°C at 1 mg/ml. L-azaserine and thymidine
(both from Sigma) were added directly to tissue culture
medium. 6-thioguanine and hypoxanthine (both from
Sigma) were dissolved in 5 M NaOH and immediately
added to the tissue culture medium.
Yeast strains and constructs
BY4741 haploid Saccharomyces cerevisiae cells (MATa
his3∆1 leu2∆0 met15∆0 ura3∆0) and a panel of single-gene
deletion derivatives hereof (table 1) were purchased from
EUROSCARF, Institute of Microbiology, Johann Wolfgang
Goethe University Frankfurt, Germany. The construction
of BY4741 and its deletion derivatives have been
described [65]. JN362At2–4 cells with the relevant geno-
type (MATa ura3–52 leu2 trp1 his7 ade1–2 ISE2 top2-4)
were kindly provided by Dr. John L. Nitiss, St. Jude Chil-
dren's Research Hospital, Memphis TN, USA. This strain
and the construct for functional expression of human
topoisomerase II α in yeast pMJ1 (URA3) have been
described previously [66]. All yeast strains were trans-
formed with pMJ1 to functionally express human topoi-
somerase II α in a cell cycle independent fashion. BY4741
wild-type and ∆rad6, ∆rad50, ∆rad52, ∆sae2 and ∆yku70
cells were also transformed with an empty URA3 vector
(pYX112). The ICRF-187 and m-AMSA sensitivity of
pYX112-transformed cells was assessed to assure that the
drug sensitivity of the pMJ1-transformed cells (Table 2,
S1) is related to the ectopic expression of human topoi-
somerase II α in the cells, which was the case. Transforma-
tion and selection was carried out according to standard
procedures using lithium acetate cell wall permeabilisa-
tion and PEG-mediated DNA uptake by using single-
stranded DNA as carrier as described [67]. Selection was
done on SC-URA plates. Three independent pMJ1-trans-
formed yeast clones were selected and propagated for each
transformation. All strains were propagated at 30°C, to be
subsequently used in clonogenic assays at 34°C.
Yeast clonogenic assay
The clonogenic sensitivity of the yeast cells towards ICRF-
187 and m-AMSA was determined using a clonogenic
assay essentially performed as described in [7]. Briefly,
overnight cultures of the strains were grown in SC-URA
medium at 34°C at 200 rpm. Cells in log phase were
diluted to 2 × 106 cells/ml in pre-warmed YPD medium,
and 3 ml cultures were exposed to different concentra-
tions of drug at 34°C for 22.5 hours. After drug exposure
the samples were diluted up to 105 times (depending on
the combination of strain and drug used) in distilled ster-
ile water. Yeast cells that were not diluted before plating
were spun down by brief centrifugation, and re-suspended
in the same volume of sterile water. Next, 200 µl of
diluted cells were transferred to SC-URA plates, which
were incubated for 5 days at 30°C before counting. 200 to
600 colonies were typically counted for each drug concen-
tration in each single experiment. Finally, the relative sur-
vival at the different drug concentrations as compared to
the no drug sample was calculated to generate dose-
response curves. For each combination of yeast strain and
drug, at least three dose-response curves were generated
using pMJ1-transformed cells from at least two independ-
ent clones (mostly from three).
Yeast microarray gene expression analysis
Microarray experiments were performed with yeast strain
JN362t2–4 transformed with pMJ1 to functionally express
human topoisomerase II α. Fresh colonies were inocu-
lated into YPD medium and grown overnight at 34°C,
180 rpm. The cultures were then diluted to obtain an
OD600 of 0.2. Cultures of 50 ml in YPD medium were first
grown for two hours to assure exponential growth of the
cells. 1 mg/ml ICRF-187 or 50 µg/ml m-AMSA (equitoxic
concentrations) were then added to the cell cultures (a no-
drug sample was also included), and the cells were grown
for an additional two hours. Each treatment was per-
formed in duplicate. The used concentration of both
drugs resulted in a reduction in the clonogenecity of the
cells of 50 %. After treatment cells were harvested by cen-
trifugation. Total RNA was isolated by the hot acidic phe-
nol method [69]. All the steps for cDNA synthesis, cRNA
synthesis, biotin labeling and array hybridization to
Affymetrix S98 yeast arrays were performed as described
in the Affymetrix GeneChip Expression Analysis Technical
Manual (Affymetrix), and performed at the microarray
core facility at Rigshospitalet, Copenhagen Denmark.
Briefly, cDNA was synthesized from 5 µg RNA using a
(dT)24 primer containing a T7 RNA polymerase promoter
sequence and SuperScript II reverse transcriptase (Invitro-
gen) for 1 h at 42°C followed by second-strand synthesis
using DNA polymerase I and RNase H digestion followed
by isolation of cDNA using GeneChip Sample Cleanup
Module (Affymetrix). The cDNA was used as template for
synthesis of biotin-labeled cRNA by incubation withBMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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biotin-labeled ribonucleotides and T7 RNA polymerase
for 5 h at 37°C. Biotin-labeled cRNA was purified using
GeneChip Sample Cleanup Module. Biotinylated cRNA
was fragmented and 15 µg used for hybridization to
Affymetrix Yeast Genome S98 arrays at 45°C for 16 h as
described in the Affymetrix users' manual. Washing and
array staining with streptavidin-phytoerythrin were per-
formed using the GeneChip Fluidics Station 400 and
scanning was performed with a Gene Array Scanner G25
(Agilent technology). Data was analyzed using the DNA-
Chip Analyzer (dChip) software [70].
Real-time PCR analysis
The RNA preparations used for microarray analyses were
also used for real-time PCR. This analysis was performed
on an ABIPrism 7900HT (Applied Biosystems). RNA sam-
ples were DNase treated using the DNA-free™ DNase treat-
ment and removal kit (Ambion), and RNA concentrations
were measured before conversion to cDNA using the Taq-
Man RT kit (Applied Bioscience). Priming was performed
by random hexamers converting 2 µg RNA pr 100 µl reac-
tion volume, to make 20 ng/µl cDNA. Primers were
designed for coding sequences from the Saccharomyces
genome database http://www.yeastgenome.org using the
Primer 3 input program http://www.broad.mit.edu/cgi-
bin/primer/primer3_www.cgi. All primers were pur-
chased at DNA Technology A/S, with melting tempera-
tures close to 60°C. Reaction mixtures containing the
following components at the indicated end-concentra-
tions were prepared. To make a total of 40 µl in sterile
water, 20 µl 1x SYBR® green PCR master mix (Applied Bio-
systems), 250 nM forward primer, 250 nM reverse primer,
and 5 ng template was mixed. Cycling conditions: 95°C
for 10 min, followed by 40–45 cycles of 95°C for 15 s and
60°C for 60 s. Relative values of gene expression were cal-
culated with untreated samples as calibrator, and normal-
ized to levels of actin, according to the 2-∆∆Ct method [71]
and (User bulletin #2, AbiPrism 7700 Sequence Detection
System, Applied Biosystems) after primer optimisation
and target efficiency evaluation. The following primers
were used:
HUG1-forward, AGGCCTTAACCCAAAGCAAT;
HUG1-reverse, TCTTGTTGACACGGTTGCTC;
RNR3-forvard, ATGCATCTCCAGTTCCATCC;
RNR3-reverse, GGGGCAACACTATCTTCCAA;
RAD51-forward, GTGGCGGTGAAGGTAAGTGT;
RAD51-reverse, GTCTAATCCGAACCGCTGAG;
RAD54-forward, CTAAAGCAGGTGGGTGTGGT;
RAD54-reverse, CTTGTTGATCAGCAGCAGGA;
ACT1-forward, CGGTGATGGTGTTACTCACG;
ACT1-reverse, GGCCAAATCGATTCTCAAAA.
Mammalian cells
The CHO cell lines AA8, irs1SF, CXR3, V3-3, and the ham-
ster lung fibroblast cell line SPD8 were kindly provided by
Dr Thomas Helleday, University of Sheffield, UK. AA8 is a
wild-type cell line. The AA8-derived irs1SF cell line is
XRCC3-defective and has reduced levels of HR [37]. CXR3
is a human-XRCC3-cosmid complemented strain of
irs1SF, which is proficient in HR [37]. The V3-3 cell line is
DNA-PKcs-deficient and consequently deficient in NHEJ
[38]. The SPD8 cells carry a non-functional hprt gene that
can be repaired by HR [39]. HPRT+ cells can then be
selected on HAsT medium containing hypoxanthine, L-
azaserine and thymidine. When SPD8 cells were not used
in the recombination assay they were propagated in
medium supplemented with 6-thioguanine to select
against spontaneous reversion to the HPRT+ phenotype.
Human SCLC OC-NYH cells have been described [72].
Hamster cells were propagated in DMEM medium and
OC-NYH cells were propagated in RPMI-1640 medium.
All cell culture media were supplemented with 10 % fetal
calf serum and 100 U/ml penicillin-streptomycin. Cells
were grown in a humidified atmosphere containing 5 %
CO2 in the dark at 37°C.
Determination of topoisomerase II activity in crude cell 
extracts
Topoisomerase II activity in crude extract was determined
by using a decatenation assay previously described [68].
Briefly, 200 ng 3H labeled kDNA isolated from C. fascicu-
lata  was incubated with increasing amounts of crude
extracts in 20 µl reaction buffer containing 10 mM TRIS-
HCl pH 7.7, 50 mM NaCl, 50 mM KCl, 5 mM MgCl2, 1
mM EDTA, 15 µg/ml BSA and 1 mM ATP for 20 min at
37°C. After addition of 5x stop buffer (5 % Sarkosyl,
0.0025 % bromophenol blue and 50 % glycerol), unproc-
essed kDNA network and decatenated DNA circles were
separated by filtering, and the amount of unprocessed
kDNA in each reaction was determined by scintillation
counting. The amount of crude extract required to fully
decatenate 200 ng of kDNA under these assay conditions
(which is equivalent to 1 U of catalytic activity) was then
determined, and the specific activity of the crude extract
was calculated as U/µg protein.
Mammalian clonogenic assay
Four hours prior to continuous treatment with either
ICRF-187 or m-AMSA, 250 cells of each of the hamster cell
lines were plated onto 100 mm dishes. After 7 days colo-
nies were fixed and strained in methylene blue inBMC Pharmacology 2004, 4:31 http://www.biomedcentral.com/1471-2210/4/31
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methanol (4 mg/ml), and colonies with more than 50
cells were counted. Finally, the relative survival compared
to the no drug treatment was calculated, and plotted
against drug concentrations to generate dose-response
curves. 150 – 250 colonies were typically counted in the
"no drug" dishes.
Mammalian homologous recombination assay
A mammalian recombination assay was performed as
described [39]. Briefly, 1 × 106 SPD8 cells were inoculated
into 75 cm2 flasks. When transferred, 6-thioguanine was
omitted from the medium. Cells were trypsinised and
resuspended in 10 ml medium at 100,000 cells/ml, and
exposed to the indicated drug concentrations for 24
hours. To determine clonogenic survival, for each drug-
treatment 500 cells were transferred to each of two 100
mm petri dishes containing 10 ml of non-selecting
medium and the cells were cultured for 7 days. For selec-
tion of recombination events, 300,000 cells were
transferred to each of three 100 mm petri dishes contain-
ing 10 ml medium supplemented with 50 µM hypoxan-
thine, 10 µM L-azaserine and 5 µM thymidine and
selection was carried out for 10 days. Colonies were fixed
by using methylene blue in methanol (4 mg/ml) and
counted. Finally, the recombination frequency was deter-
mined as the plating efficiency in recombination selective
medium divided by the plating efficiency in normal
medium, for all concentrations of ICRF-187 or m-AMSA.
To enable comparison of recombination frequency at
equitoxic levels of m-AMSA and ICRF-187, the recombi-
nation frequency was plotted against the relative clono-
genic survival of cells receiving only drug.
Histone purification
Human SCLC OC-NYH cells were grown to sub-conflu-
ence and histones were extracted as follows. After the rel-
evant drug treatments, the cells were pelleted and washed
in cold PBS, and lysed in lysis buffer (10 mM TRIS-HCl pH
= 6.5, 50 mM Sodium Bisulphate, 1% Triton X-100, 10
mM MgCl, 8.6% sucrose) at 4°C by applying 20 strokes in
a tight fitting Dounce homogenizer. Released nuclei were
pelleted by centrifugation at 2500 g for 10 min at 4°C,
and washed in lysis buffer followed by wash buffer (10
mM TRIS-HCl, 13 mM EDTA pH 7.4). The pellet was next
resuspended in 100 µl ice-cold 0.4 M H2SO4, and incu-
bated for 1 hour at 4°C prior to centrifugation. The super-
natant was transferred to a clean tube and 1 ml ice-cold
acetone was added followed by incubation overnight for
histone precipitation. After centrifugation, the pellet was
air-dried and resuspended in 40 µl H2O, and the protein
concentration was determined by Bradford protein assay
(Bio-Rad Laboratories)
γH2AX western blot
Western blotting was performed by loading 10 µg of total
histones on a 4–12% gradient gel (NuPageTM Bis-Tris
Gel, Invitrogen). Separated proteins were transferred to
nitrocellulose membranes (Bio-Rad) which were blocked
in 10% skimmed milk (Fluka) and incubated overnight
with anti γH2AX primary antibody diluted 1:500 (Upstate
Technology, cat no 16–193) followed by detection with
goat-anti-mouse (Amersham) 1:2000 for one hour. Detec-
tion with ECL Plus™(Amersham) was performed by scan-
ning on STORM™ 840 (Molecular Dynamics Inc), on
which the image was optimized and bands quantified by
Image Quant™ version 5.0 (Molecular Dynamics).
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